Goldman Sachs downgraded Luye Pharma to Sell from Neutral with a price target of HK$3.73, up from HK$3.68. The firm sees modest product sales growth in the coming years and views earnings improvement from potential debt pay-down as reflected in the share price, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>